Combined Graphene Oxide with 2-Methoxyestradiol for Effective Anticancer Therapy in-vitro Model

Area of Science:

• Biomaterials Science
• Nanotechnology
• Oncology

Background:

• Graphene oxide (GO) and reduced graphene oxide (rGO) offer unique properties for drug delivery.
• 2-methoxyestradiol (2-ME) is a therapeutic agent with potential anticancer activity.
• Improving the bioavailability and targeted delivery of 2-ME is crucial for its efficacy.

Purpose of the Study:

• To describe the invention of GO/rGO functionalized with 2-ME.
• To evaluate the anticancer effectiveness of the novel GO-2-ME conjugate.
• To elucidate the mechanism of action, including PTP1B inhibition.

Main Methods:

• Synthesis of GO/rGO functionalized with 2-ME via hydrogen bonding.
• In vitro cytotoxicity assays using A375 melanoma and 143B osteosarcoma cell lines.
• In vivo studies to assess anticancer effectiveness.

Main Results:

• GO/rGO functionalization enables effective binding of 2-ME through hydrogen bonds.
• The GO-2-ME conjugate demonstrated significant anticancer effectiveness against melanoma and osteosarcoma cells.
• A key finding is the inhibition of PTP1B phosphotyrosine phosphatase by GO-2-ME, a mechanism not observed with 2-ME alone.

Conclusions:

• GO/rGO functionalized with 2-ME represents a promising strategy for cancer therapy.
• This approach enhances 2-ME bioavailability and facilitates targeted delivery.
• The conjugate enables selective elimination of malignant cells through controlled cell signaling and PTP1B inhibition.